Co-Founder,Chairman, Member of the Board of Directors
Dr. Ishi has served as President, Chief Executive Officer and Director of REGiMMUNE since June 2014. Dr. Ishii is the team leader of the Laboratory for Vaccine Design at the RIKEN Research Center for Allergy and Immunology. His research is focused on the development of vaccines for Japanese cedar pollinosis. Previously, as a researcher at Kirin Pharmaceutical Division and the La Jolla Institute for Allergy & Immunology, he studied the regulatory system for IgE antibody responses in the laboratory of Dr. Kimishige Ishizaka, a pioneer in the discovery of the IgE antibody. To explore immunoregulatory systems against allergic reactions, Dr. Ishii moved to the Agency of Industrial Science and Technology in the Ministry of International Trade and Industry, which was reorganized to the National Institute of Advanced Industrial Science and Technology (AIST). Dr. Ishii is also a visiting associate professor in the Division of Immune Regulation at the graduate school of Chiba University. He received his BS, MS and PhD degrees in Chemistry from the Tokyo Institute of Technology and is a member of the American Association of Immunologists, Japanese Society of Immunology and Japanese Society of Allergology.
President&CEO/ Member of the Board
Mr. Kosuda joined REGiMMUNE as chief financial officer in 2013. In this role, he is responsible for finance, investor relations, operations, strategy and corporate development.
He has over twenty years of extensive experience in financial area throughout his experience at Deloitte Tohmatsu and PwC as professional consultant and his own accounting firm to help emerging companies. Prior to join REGiMMUNE, he served as CFO at Sparx Asset Management where he led the first IPO of an asset management company in Japan.
He has an BA degree in Economics from the Keio University in Japan and is a Chartered Accountant.